An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Molgramostim (Primary)
- Indications Bacterial infections; Mycobacterial infections; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- Focus Therapeutic Use
- Acronyms OPTIMA
- Sponsors Savara Pharmaceuticals
- 16 Mar 2020 Status changed from active, no longer recruiting to completed.
- 12 Mar 2020 According to a Savara Pharmaceuticals media release, the company intends to submit the full data set from this study for consideration at an upcoming scientific conference.
- 18 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Jan 2020.